How a well-traveled brain cancer drug turned into an $8 million payday for an East Bay firm

A play-by-play that over 20 years evolved to include six companies, a prominent research institute, the National Institutes of Health and a key incentive for companies to develop drugs for rare childhood diseases.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks